Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Precision Breast Cancer Screening: Moving from Debate to Wisdom _______Laura Esserman, MD, MBADirector, UCSF Carol Franc Buck Breast Care Center@drlauraessermanSeptember 18, 2019
Diane HeditsianWISDOM Study Research Advocate & Communications Consultant
@dianeheditsian
2
Laura Esserman• Has nothing to disclose.
Diane Heditsian• Has nothing to disclose.
3
Audience Poll
• How many women are getting mammography screening for breast cancer?
• How many women believe there is complete agreement on when women should start and how often they should be screened?
• How many women know their own breast cancer risk?
4
Years of Policy Controversy & ConflictWISDOM will provide data required to inform professional societies and resolve discordant recommendations
Professional Society Screening Age Frequency
USPSTF 40 – 4950 – 74
Shared decision on whether to screen Biennially (for average risk)
ACS 45 – 5555 – until life expectancy < 10 years.
AnnuallyBiennially
ACR / SBI 40 – until life expectancy < 5 -7 years. Annually
NCCN 40 – until life expectancy < 10 years. Annually
ACOG 40 – 4950 – 74
Shared decision on whether to screen Shared decision: Annual or Biennial
ACP (new: April 2019) 40 – 4950 – 74
Shared decision on whether to screen Biennially
5
Breast Screening Controversy Puts Women in the Middle
Polarized Views Confuse MDs too
6
Old Paradigm
7
New Paradigm: Breast Cancer is not a single diseaseTumor progression and Benefit (lack of) from Screening
8
Breast Cancer Screening Today• Mired in controversy• Based on 30-year-old medical science• Age-based• Low risk women are over-screened
• false positive recalls and benign biopsies • High-risk women are under-screened missing lethal tumors• Catchy Public Health Messages miss the complexity
• “Mammograms Save Lives” and “Early Detection Saves Lives” • Resource intensive in aggregate: $8 - $10 billion annually
9
“One Size Does NOT Fit All”
10
Unprecedented Opportunity: Advances in Science and Technology
11
What Breast Cancer Screening Could Be: Personalized
• Leverages advances in: • Biology of breast cancer• Risk-assessment • Genetics
• More effective at finding “clinically meaningful” cancers • Personalized and precise for each individual woman• Integrated with risk reduction strategies• More cost-effective
12
Comprehensive risk prediction model• Validated high-impact risk factors including
• Exposures/Lifestyle• Breast density• 9 breast cancer genes• SNPs polygenic risk score
• 76303 SNPs
• Tailor screening/prevention plans • Age to start/stop• Frequency• Screening modality• Risk reduction
13
Pragmatic Trial Design: Preference Tolerant RCT
14
Wisdom Study AimsDetermine if personalized screening (as compared to annual screening):1. Is as safe 2. Is less morbid 3. Is more accepted by women4. Enables prevention5. Has greater health care value
15
Risk Reduction: Breast Health Decisions Tool• Automated integration of risk education tool
• Includes risk factors and interventions to lower risk
• Threshold for outreach (personalized arm): Top 2.5 % risk by age group
16
Breast Health Decisions Tool
17
Transformative Trials That Evolve: WISDOM Study Structure
• All reporting is automated using the WISDOM platform• Offered across several nationwide sites
• California, Dakotas, Iowa, Minnesota, Illinois, Alabama, Louisiana
18
PCORI Principles• Results ready in a timely way
• Used a surrogate endpoint- no increase in stage 2B cancers• Tests had to be covered by the study (payors participating)
• Coverage with Evidence Progression model• Compared to annual, cost saving over time• Champion: Blue Cross Blue Shield and self-insured employers
• Stakeholder Engagement• Annual stakeholder meetings to project results• All guideline makers, payors, providers at the table
19
Why is this study critical for women?• Answers a big and intractable question • Breast cancer screening can leverage precision
medicine • Begin to learn who is at risk/for what kind of breast cancer • Provides a framework to determine risk, improve screening,
educate/involve women and integrate risk reduction • Breaks down barriers so more women can participate• Answers will be relevant to all communities of women
20
What Does it Take For a Paradigm to Shift?
What results will have enough impact to inform guidelines?
What are the right early endpoints?
How best to educate MDs and women?
Annual Stakeholder Meeting: Full day each year
21
WISDOM Innovations• Use of established tests in new ways• Coverage with evidence development/progression• Virtual trial design
• Trial comes to the participant not vice versa
• Technology platform with embedded analytics• All stakeholders at the table from beginning
• reduce time to implement trial results
• Risk model is updated as new data emerges• Patient Reported Outcomes• Patient education and risk communication (BHD Tool)• Bioethics Committee & Embedded Ethics Study
22
Wisdom Recruitment over time
23
Lessons Learned• Opposing views will always be encountered
• Radiology community in US feels that less than“annual screening” hurts women
• Models will always improve• Build an infrastructure that allows study to evolve as knowledge evolves
• Test the concept of personalization based on best knowledge • Allow for improvements in models
• Much more difficult to get payers to partner than anticipated!• Recruiting diverse populations takes a big effort
24
Patient-Centered and Inclusive
• Spanish Translation• Outreach Materials
• Plain-language translation
• Materials modified with simpler, 6th
grade reading level
25
Everyone Benefits When Everyone Participates
26
Thank You to Partners & Stakeholders
27
28
Thank You!Laura Esserman, MD, MBADirector, UCSF Carol Franc Buck Breast Care Center
@drlauraesserman
September 18, 2019
Diane HeditsianWISDOM Study Research Advocate & Communications Consultant
@dianeheditsian